

**From:** SANTE PHARMACEUTICALS B5  
**Sent:** lundi 23 octobre 2017 15:11  
**To:** [REDACTED]  
**Cc:** [REDACTED] GROW D3  
**Subject:** RE: Copenhagen Economics study on economic impact of SPC, pharmaceutical incentives and rewards in Europe

Dear [REDACTED],

We refer to your message dated 2 October 2017 concerning the study on the impact of supplementary protection certificates, pharmaceutical incentives and rewards on innovation, availability and accessibility of medicinal products in the EU.

The study is currently ongoing and is carried out by the consultant Copenhagen Economics. As you rightly pointed out in your message, the Terms of Reference of the study foresee that stakeholders consulted should represent all relevant and interested parties (including, in particular, industry, patients, health care professionals, consumer and public health organisations, payers, academia.....) in a balanced way and at a European level.

Concerning the involvement of payers, the Commission facilitated a meeting between the contractor and Member States on 26 September 2017, with the view to gather also the views of payers. Although the national statutory social security organisations were not particularly represented with Member States' delegations, Member States expressed views regarding budgetary constraints and gave examples of budgetary impacts.

The contractor has no additional interviews foreseen with payers' representatives. However, I would like stress that your contributions are always welcome as your input on the impact of the use of incentives on pricing strategies and policies is essential.

Best regards,

Unit "Medicines: policy, authorisation and monitoring"



European Commission  
DG Health and Food Safety

---

*This message represents solely the views of its author and cannot be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.*

---

**From:** SANTE PHARMACEUTICALS B5  
**Sent:** Friday, October 13, 2017 3:02 PM  
**To:** [REDACTED] GROW D3  
**Cc:** [REDACTED] SANTE PHARMACEUTICALS B5  
**Subject:** RE: Copenhagen Economics study on economic impact of SPC, pharmaceutical incentives and rewards in Europe

Dear [REDACTED],

Thank you for your message. We have passed on your messages to the person responsible for the study on incentives, and we will get back to you in the coming days.

Best regards,

Unit "Medicines: policy, authorisation and monitoring"



**European Commission**  
DG Health and Food Safety

---

*This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.*

---

**From:** [REDACTED]  
**Sent:** Friday, October 13, 2017 12:41 PM  
**To:** SANTE PHARMACEUTICALS B5; GROW D3  
**Cc:** [REDACTED]  
**Subject:** ([REDACTED] sante.ddg1.b.5(2017)5458830) Fw: Copenhagen Economics study on economic impact of SPC, pharmaceutical incentives and rewards in Europe

Dear Sir or Madam

I would refer you to my email below sent to you on 2 October. Regretfully, I still have not received a reply from your respective services.

I would appreciate it if you could forward this message to the relevant persons concerned, with the request that they get back to me as soon as possible.

Best regards



[REDACTED]  
**Maison européenne de la protection sociale**  
[REDACTED]

[www.esip.eu](http://www.esip.eu)

Twitter: [@ESIP\\_EU](https://twitter.com/ESIP_EU)

---

**From:** [REDACTED]

**Sent:** 02 October 2017 16:30

**To:** [Sante-pharmaceuticals-B5@ec.europa.eu](mailto:Sante-pharmaceuticals-B5@ec.europa.eu); [GROW-D3@ec.europa.eu](mailto:GROW-D3@ec.europa.eu)

**Cc:** [REDACTED]

**Subject:** Copenhagen Economics study on economic impact of SPC, pharmaceutical incentives and rewards in Europe

Dear Sir/Madam

In follow-up to the DG GROW multistakeholder workshop held on 12 September, I would like reiterate my concerns that as representatives of the national statutory social security organisations in the EU (the payers) ESIP has yet to be contacted by Copenhagen Economics as regards the STUDY they have been contacted to perform ON THE ECONOMIC IMPACT OF SUPPLEMENTARY PROTECTION CERTIFICATES, PHARMACEUTICAL INCENTIVES AND REWARDS IN EUROPE.

In this context, the TENDER SPECIFICATIONS specifically refer on page 25 to those stakeholders who should be consulted in the process of the study as:

"<sup>4</sup> The stakeholders consulted should represent all relevant and interested parties (including **in particular**, industry, patients, health care professionals, consumer and public health organisation, **payers**, academia.....) in a balanced way and at a European level."

Could you please let me know the current state of affairs as regards the foreseen consultations with stakeholders, in particular the payers and let me know when we might be contacted or how we might contact Copenhagen Economics to ensure that we have the opportunity to give our input?

Many thanks in advance for your help in this matter.

Best regards



[REDACTED]

[REDACTED]

*Maison européenne de la protection sociale*

[REDACTED]

[REDACTED]

[REDACTED]

[www.esip.eu](http://www.esip.eu)

Twitter: [@ESIP\\_EU](https://twitter.com/ESIP_EU)